In two recent articles, Gastroenterology & Endoscopy News incorrectly
stated that Linzess (linaclotide), which received FDA approval last August to
treat chronic idiopathic constipation and to treat irritable bowel syndrome
with constipation, is indicated for individuals “who do not respond to standard
treatments.” This phrase is inconsistent with the FDA-approved indication for
Linzess, which does not contain this stipulation. “It is not necessary to fail another